Literature DB >> 27593430

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?

N R Srinivas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27593430     DOI： 10.1111/apt.13743

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  1 in total

1.  Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.

Authors:  Jiri Bronsky; Ivana Copova; Denis Kazeka; Tereza Lerchova; Katarina Mitrova; Kristyna Pospisilova; Miroslava Sulovcova; Kristyna Zarubova; Ondrej Hradsky
Journal:  Clin Transl Gastroenterol       Date:  2022-05-01       Impact factor: 4.396
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.